Table 5.
Frequency of dizziness by study group adjusted by gender, age, anaemia at inclusion
|
Dizziness | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Day 1 |
|
Day 2 |
|
|
Day 3 |
|
|||
| n (%) | aOR** (95%CI) | p value | n (%) | aOR (95%CI) | p value | n (%) | aOR (95%CI) | p value | |
|
*Treatment |
|
|
|
|
|
|
|
|
|
|
AL (n = 153) |
17 (11.1%) |
1 |
|
8 (5.2) |
1 |
|
11 (7.1) |
1 |
|
| AM (n = 157) | 35 (22.3%) | 2.2 (1.1-4.4) | .02 | 61 (38.8) | 12.5 (5.5 – 28.1) | .001 | 58 (38.1) | 10.2 (4.7-22.3) | .001 |
* AM = Artesunate-mefloquine; AL = Artemether-Lumefantrine.
**aOR: adjusted odds ratio. The analysis of the association between dizziness and treatment was adjusted by mean haemoglobin at inclusion, age, gender.